Monoklonska protutijela u liječenju limfocitnih neoplazmi

master's thesis

• Title (english): Monoclonal antibodies in the treatment of lymphoid neoplasms
• Author: Tomislav Brblić
• Mentor: Vlatko Pejša (mentor)
• Committee member: Rajko Kušec (predsjednik povjerenstva)
• Committee member: Nikola Đaković (član povjerenstva)
• Committee member: Vlatko Pejša (član povjerenstva)
• Granter: University of Zagreb; School of Medicine; (Department of Internal Medicine); Zagreb
• Defense date and country: 2017-07-14, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Internal Medicine
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Basic Medical Sciences; Pharmacology

Abstract

Limfocitne neoplazme heterogena su skupina bolesti koje nastaju klonskom ekspanzijom i proliferacijom limfocita, bijelih krvnih stanica. Prema najnovijoj klasifikaciji SZO-a iz 2016. dijele se u 3 skupine: tumori zrelih limfocita B, tumori zrelih limfocita T i NK, i Hodkinov limfom. Posebna klasifikacija postoji za akutne leukemije. U njihovu se liječenju primjenjuju različiti postupci: radioterapija, kemoterapija, transplantacija matičnih stanica koštane srži, a u novije vrijeme i terapija inhibitorima tirozin kinaze, Bcl-2 inhibitorima, imunomodulatorima i monoklonskim protutijelima. Monoklonska protutijela su imunoglobulini nastali od jednog klona plazma-stanica, što znači da imaju samo jednu specifičnost za antigen. S obzirom da ljudski limfociti na svojoj površini imaju niz specifičnih molekula, idealna su meta za djelovanje nekog monoklonskog protutijela, koja su danas nezaobilazna terapijska opcija, ne samo u hematologiji, već i u brojnim drugim granama medicine. Ovaj pregledni rad donosi prikaz farmakokinetičkih i farmakodinamičkih svojstava, indikacija i kliničkog profila najčešće upotrebljavanih monoklonskih protutijela u liječenju limfocitnih neoplazmi.

Abstract (english)

Lymphoid neoplasms are a heterogeneous group of diseases deriving from clonal expansion and proliferation of lymphocytes, white blood cells. According to the latest classification of WHO from 2016, they are divided into 3 groups: mature B-cell lymphoid neoplasms, mature T- and NK-cell neoplasms, and Hodgkin's lymphoma. There is a special classification for acute leukemias. Various procedures are used in their treatment: radiotherapy, chemotherapy, stem cell transplantation, and recently tyrosine kinase inhibitors, Bcl-2 inhibitors, immunomodulators and monoclonal antibodies. Monoclonal antibodies are immunoglobulins produced by a single plasma cell clone, which means they only bind to one unique antigen. Since human lymphocytes have a number of specific molecules on their surface, they are an ideal target for the action of a monoclonal antibody, which is nowadays an inevitable therapeutic option not only in hematology, but also in many other branches of medicine. This review describes the pharmacokinetic and pharmacodynamic properties, indications and clinical profile of the most commonly used monoclonal antibodies in the treatment of lymphoid neoplasms.

• Keywords: limfocitne neoplazme; monoklonska protutijela; hematologija
• Keywords (english): lymphoid neoplasms; monoclonal antibodies; hematology
• Language: croatian
• URN:NBN: urn:nbn:hr:105:295137
• Study programme: Title: Medicine; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access
• Created on: 2018-04-16 08:37:10